Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib Discontinuation in CML (D-STOP)
NCT01627132Phase 2Unknown
- Sponsor
- Shimousa Hematology Study Group
- Start
- Feb 2012
- Primary completion
- Feb 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Shimousa Hematology Study Group. Primary endpoint: Overall probability of maintenance of complete molecular remission at 12 months after stopping dasatinib. Status: unknown.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01627132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01627132.